Prevail will perform in vitro and in vivo studies on some of the adeno-associated virus capsids of Sangamo. Credit: Kateryna Kon/Shutterstock.com.

Sangamo Therapeutics has signed an evaluation and option agreement with Eli Lilly and Company’s subsidiary Prevail Therapeutics to evaluate adeno-associated virus (AAV) capsids.

Prevail will perform in vitro and in vivo studies on some of Sangamo’s AAV capsids.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In exchange, Sangamo will receive an upfront payment. It will also receive exercise fees and developmental milestones of $415m, upon Prevail’s exercising its option for all targets.

If the product is approved in Europe and the US for each target, Sangamo will also obtain commercial milestones of $775m, along with tiered royalties.

These royalties are provided based on net sales of Prevail products incorporating the licensed capsids.

See Also:

In addition, Prevail will lead all activities, including manufacturing, commercialisation and development of products incorporating the capsids.

Sangamo chief operating officer Mark McClung stated: “We believe these innovative new capsids have the potential to broaden addressable indications in the field of genomic medicines, opening up potential new treatment options for patients in need.

“This agreement highlights the value of our AAV capsid engineering programme, not only for the discovery of novel capsids for the advancement of our wholly owned programmes but also as an opportunity to work with partners to broaden the scope of diseases addressable with AAV gene therapy.

“We are thrilled to work with Prevail to evaluate our novel capsids for neurological targets and are pleased that other genomic medicine companies recognise their potential value.”